Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Monotherapy or in combination w/ MTX for active psoriatic arthritis in adults who have responded inadequately to, or who are intolerant to ≥1 disease-modifying anti-rheumatic drug therapies.
Hypersensitivity. Not to be given in patients w/ active TB. Increased rate of infections eg, URTI, oral candidiasis, conjunctivitis & tinea infections. Patients w/ clinically important chronic infections; inflammatory bowel disease eg, Crohn's disease & ulcerative colitis. Not to be used w/ live vaccines. Renal or hepatic impairment. Women of childbearing potential should use effective contraception during & at least 10 wk after treatment. Avoid use during pregnancy. Lactation. Childn & adolescents ≤2-18 yr. Elderly ≥75 yr.
Sign Out
